| ［1］ |
Persson M, Harman KE, Vinogradova Y, et al. Incidence, prevalence and mortality of bullous pemphigoid in England 1998-2017: a population⁃based cohort study［J］. Br J Dermatol, 2021,184（1）:68⁃77. doi: 10.1111/bjd.19022.
|
| ［2］ |
Cyr P, Lim D, Caruana M, et al. Bullous pemphigoid⁃associated mortality rate in a Canadian tertiary referral centre［J］. J Cutan Med Surg, 2022,26（4）:386⁃392. doi: 10.1177/1203475422108 8562.
|
| ［3］ |
Chen X, Zhang Y, Luo Z, et al. Prognostic factors for mortality in bullous pemphigoid: a systematic review and meta⁃analysis［J］. PLoS One, 2022,17（4）:e0264705. doi: 10.1371/journal.pone.026 4705.
|
| ［4］ |
Kridin K, Shihade W, Bergman R. Mortality in patients with bullous pemphigoid: a retrospective cohort study, systematic review and meta⁃analysis［J］. Acta Derm Venereol, 2019,99（1）:72⁃77. doi: 10.2340/00015555⁃2930.
|
| ［5］ |
Kridin K, Schwartz N, Cohen AD, et al. Mortality in bullous pemphigoid: a systematic review and meta⁃analysis of standardized mortality ratios［J］. J Dermatol, 2018,45（9）:1094⁃1100. doi: 10.1111/1346⁃8138.14503.
|
| ［6］ |
Bastuji⁃Garin S, Joly P, Lemordant P, et al. Risk factors for bullous pemphigoid in the elderly: a prospective case⁃control study［J］. J Invest Dermatol, 2011,131（3）:637⁃643. doi: 10. 1038/jid.2010.301.
|
| ［7］ |
Roujeau JC, Lok C, Bastuji⁃Garin S, et al. High risk of death in elderly patients with extensive bullous pemphigoid［J］. Arch Dermatol, 1998,134（4）:465⁃469. doi: 10.1001/archderm.134.4. 465.
|
| ［8］ |
毕兆华, 冯博惠, 李久宏, 等. 大疱性类天疱疮患者发生感染的分析［J］. 中国皮肤性病学杂志, 2019,33（4）:400⁃404. doi: 10.13735/j.cjdv.1001⁃7089.201810017.
|
| ［9］ |
Holtsche MM, Goletz S, van Beek N, et al. Prospective study in bullous pemphigoid: association of high serum anti⁃BP180 IgG levels with increased mortality and reduced Karnofsky score［J］. Br J Dermatol, 2018,179（4）:918⁃924. doi: 10.1111/bjd.16553.
|
| ［10］ |
Joly P, Benichou J, Lok C, et al. Prediction of survival for patients with bullous pemphigoid: a prospective study［J］. Arch Dermatol, 2005,141（6）:691⁃698. doi: 10.1001/archderm.141.6.691.
|
| ［11］ |
Phoon YW, Fook⁃Chong SM, Koh HY, et al. Infectious complications in bullous pemphigoid: an analysis of risk factors［J］. J Am Acad Dermatol, 2015,72（5）:834⁃839. doi: 10.1016/j.jaad.2015.01.029.
|
| ［12］ |
中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会. 自身免疫性表皮下大疱病诊疗共识（2022）［J］. 中华皮肤科杂志, 2022,55（1）:1⁃11. doi: 10.35541/cjd.20210532.
|
| ［13］ |
楼小航, 刘继峰, 吴纪龙, 等. 大疱性类天疱疮患者感染分析［J］. 中华医院感染学杂志, 2017,27（9）:2009⁃2011,2019. doi: 10.11816/cn.ni.2017⁃163672.
|
| ［14］ |
Kridin K，Bergman R. Assessment of the prevalence of mucosal involvement in bullous pemphigoid［J］. JAMA Dermatol, 2019, 155（2）:166⁃171. doi:10.1001/jamadermatol.2018.5049.
|
| ［15］ |
Chen J, Mao X, Zhao W, et al. Assessment of the characteristics and associated factors of infectious complications in bullous pemphigoid［J］. Front Immunol, 2020,11:1607. doi: 10.3389/fimmu.2020.01607.
|
| ［16］ |
Miyagawa F, Nakajima A, Ogawa K, et al. Composite EBV⁃negative marginal zone lymphoma and angioimmunoblastic T⁃cell lymphoma presenting as multiple subcutaneous nodules［J］. Eur J Dermatol, 2020,30（4）:427⁃429. doi: 10.1684/ejd.2020.3810.
|
| ［17］ |
Li F, Bian W, Wu Y, et al. Bacterial skin infections in hospitalized patients with bullous pemphigoid［J］. Adv Skin Wound Care, 2021,34（7）:365⁃370. doi: 10.1097/01.ASW.0000 752704.10152.30.
|
| ［18］ |
姚香君, 张琪, 王婷, 等. 656例自身免疫性大疱病住院患者皮肤感染的危险因素及病原学分析［J］. 中国麻风皮肤病杂志, 2021,37（8）:494⁃498. doi: 10.12144/zgmfskin202108494.
|
| ［19］ |
Ren Z, Narla S, Hsu DY, et al. Association of serious infections with pemphigus and pemphigoid: analysis of the Nationwide Inpatient Sample［J］. J Eur Acad Dermatol Venereol, 2018,32（10）:1768⁃1776. doi: 10.1111/jdv.14961.
|
| ［20］ |
Oka M, Fukumoto T. Bullous pemphigoid in which eruption developed exclusively on preexisting eruption of vitiligo vulgaris［J］. Case Rep Dermatol, 2020,12（1）:33⁃36. doi: 10.1159/000 505829.
|
| ［21］ |
Soine EJ, Nelson PS, Nesbitt LT Jr. A patient with coexistent bullous pemphigoid and primary membranous glomerulonephropathy［J］. J Am Acad Dermatol, 2009,60（6）:1042⁃1044. doi: 10.1016/j.jaad.2008.08.032.
|
| ［22］ |
Chen YJ, Juan CK, Chang YT, et al. Association between inflammatory bowel disease and bullous pemphigoid: a population⁃ based case⁃control study［J］. Sci Rep, 2020,10（1）:12727. doi: 10.1038/s41598⁃020⁃69475⁃0.
|
| ［23］ |
Narita YM, Horie C, Hirahara K, et al. Bullous pemphigoid complicated by cytomegalovirus disease as a manifestation of immune reconstitution inflammatory syndrome: retrospective analyses of our institutional cases and literature review［J］. Int J Dermatol, 2018,57（2）:202⁃208. doi: 10.1111/ijd.13799.
|
| ［24］ |
Kamiya K, Aoyama Y, Suzuki T, et al. Possible enhancement of BP180 autoantibody production by herpes zoster［J］. J Dermatol, 2016,43（2）:197⁃199. doi: 10.1111/1346⁃8138.13042.
|
| ［25］ |
Monshi B, Gulz L, Piringer B, et al. Anti⁃BP180 autoantibody levels at diagnosis correlate with 1⁃year mortality rates in patients with bullous pemphigoid［J］. J Eur Acad Dermatol Venereol, 2020,34（7）:1583⁃1589. doi: 10.1111/jdv.16363.
|
| ［26］ |
Delli FS, Sotiriou E, Lazaridou E, et al. Total IgE, eosinophils, and interleukins 16, 17A, and 23 correlations in severe bullous pemphigoid and treatment implications［J］. Dermatol Ther, 2020,33（6）:e13958. doi: 10.1111/dth.13958.
|
| ［27］ |
Kamata A, Kurihara Y, Funakoshi T, et al. Basement membrane zone IgE deposition is associated with bullous pemphigoid disease severity and treatment results［J］. Br J Dermatol, 2020,182（5）:1221⁃1227. doi: 10.1111/bjd.18364.
|
| ［28］ |
盖晓磊, 李思哲, 左亚刚. 大疱性类天疱疮患者血清及疱液嗜酸性粒细胞阳离子蛋白水平检测［J］. 中华皮肤科杂志, 2020,53（12）:1008⁃1011. doi: 10.35541/cjd.20191115.
|
| ［29］ |
Lehman JS, Khunger M, Lohse CM. Infection in autoimmune bullous diseases: a retrospective comparative study［J］. J Dermatol, 2013,40（8）:613⁃619. doi: 10.1111/1346⁃8138.12175.
|
| ［30］ |
Sugiura K, Sugiura N, Yagi T, et al. Cryptococcal cellulitis in a patient with bullous pemphigoid［J］. Acta Derm Venereol, 2013,93（2）:187⁃188. doi: 10.2340/00015555⁃1385.
|
| ［31］ |
Casals DS, Nunes Ede A, Maruta CW, et al. Disseminated cytomegalovirus disease as a cause of prolonged fever in a bullous pemphigoid patient under systemic steroid therapy［J］. J Dermatol, 2003,30（4）:332⁃336. doi: 10.1111/j.1346⁃8138.2003.tb00396.x.
|
| ［32］ |
Tremblay C, Friedmann D. Kaposi sarcoma associated with iatrogenic immunosuppression: a rare complication of bullous pemphigoid treatment［J］. J Cutan Med Surg, 2017,21（5）:449⁃451. doi: 10.1177/1203475417712247.
|
| ［33］ |
Boughrara Z, Ingen⁃Housz⁃Oro S, Legrand P, et al. Cutaneous infections in bullous pemphigoid patients treated with topical corticosteroids［J］. Ann Dermatol Venereol, 2010,137（5）:345⁃351. doi: 10.1016/j.annder.2010.03.015.
|
| ［34］ |
刘景业, 尹莉, 尹志强, 等. 45例大疱性类天疱疮初次住院患者临床回顾性分析［J］. 实用皮肤病学杂志, 2015,（4）:253⁃256. doi: 10.11786/sypfbxzz.1674⁃1293.20150404.
|
| ［35］ |
Messingham KN, Cahill MP, Kilgore SH, et al. TSST⁃1+Staphylococcus aureus in bullous pemphigoid［J］. J Invest Dermatol, 2022,142（4）:1032⁃1039.e6. doi: 10.1016/j.jid.2021.08.438.
|
| ［36］ |
Abdat R, Waldman RA, de Bedout V, et al. Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series［J］. J Am Acad Dermatol, 2020,83（1）:46⁃52. doi: 10.1016/j.jaad.2020.01.089.
|
| ［37］ |
Cao P, Xu W, Zhang L. Rituximab, omalizumab, and dupilumab treatment outcomes in bullous pemphigoid: a systematic review［J］. Front Immunol, 2022,13:928621. doi: 10.3389/fimmu.2022. 928621.
|
